ArticleClinical ophthalmology (Auckland, N.Z.)2023

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.

Joseph M Coney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.